MDM2 and Thrombocytopenia: This may contribute to the generally greater toxicity of MDM2 inhibitors for cancer cells compared to normal cells, although some haematopoetic cell lineages also appear to be sensitive, as evidenced by the dose limiting thrombocytopenia seen in the early phase clinical trials of MDM2 inhibitors [40].